{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:36:59Z","timestamp":1793036219332,"version":"4.5.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T00:00:00Z","timestamp":1718755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T00:00:00Z","timestamp":1718755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Discov."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cancer metabolic reprogramming has been recognized as one of the cancer hallmarks that promote cell proliferation, survival, as well as therapeutic resistance. Up-to-date regulation of metabolism in T-cell lymphoma is poorly understood. In particular, for human angioimmunoblastic T-cell lymphoma (AITL) the metabolic profile is not known. Metabolic intervention could help identify new treatment options for this cancer with very poor outcomes and no effective medication. Transcriptomic analysis of AITL tumor cells, identified that these cells use preferentially mitochondrial metabolism. By using our preclinical AITL mouse model, mimicking closely human AITL features, we confirmed that T follicular helper (Tfh) tumor cells exhibit a strong enrichment of mitochondrial metabolic signatures. Consistent with these results, disruption of mitochondrial metabolism using metformin or a mitochondrial complex I inhibitor such as IACS improved the survival of AITL lymphoma-bearing mice. Additionally, we confirmed a selective elimination of the malignant human AITL T cells in patient biopsies upon mitochondrial respiration inhibition. Moreover, we confirmed that diabetic patients suffering from T-cell lymphoma, treated with metformin survived longer as compared to patients receiving alternative treatments. Taking together, our findings suggest that targeting the mitochondrial metabolic pathway could be a clinically efficient approach to inhibit aggressive cancers such as peripheral T-cell lymphoma.<\/jats:p>","DOI":"10.1038\/s41420-024-02061-9","type":"journal-article","created":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T15:01:59Z","timestamp":1718809319000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Dependence on mitochondrial respiration of malignant T cells reveals a new therapeutic target for angioimmunoblastic T-cell lymphoma"],"prefix":"10.1038","volume":"10","author":[{"given":"Adrien","family":"Krug","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana","family":"Mhaidly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Tosolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Mondragon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gamze","family":"Tari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana Martinez","family":"Turtos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Paul-Bellon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahid","family":"Asnafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9a","family":"Di Mascio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Travert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Bost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Bachy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael J.","family":"Arg\u00fcello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Fourni\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Gaulard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Lemonnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1585-8117","authenticated-orcid":false,"given":"Jean-Ehrland","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9224-5491","authenticated-orcid":false,"given":"Els","family":"Verhoeyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,19]]},"reference":[{"key":"2061_CR1","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.bbabio.2010.10.012","volume":"1807","author":"C Jose","year":"2011","unstructured":"Jose C, Bellance N, Rossignol R. Choosing between glycolysis and oxidative phosphorylation: a tumor\u2019s dilemma? Biochim Biophys Acta. 2011;1807:552\u201361.","journal-title":"Biochim Biophys Acta"},{"key":"2061_CR2","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1126\/science.1160809","volume":"324","author":"MG Vander Heiden","year":"2009","unstructured":"Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029\u201333.","journal-title":"Science"},{"key":"2061_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1600-065X.2012.01150.x","volume":"249","author":"GJW van der Windt","year":"2012","unstructured":"van der Windt GJW, Pearce EL. Metabolic switching and fuel choice during T-cell differentiation and memory development. Immunol Rev. 2012;249:27\u201342.","journal-title":"Immunol Rev"},{"key":"2061_CR4","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau1167","volume":"11","author":"L Zhang","year":"2019","unstructured":"Zhang L, Yao Y, Zhang S, Liu Y, Guo H, Ahmed M, et al. Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma. Sci Transl Med. 2019;11:eaau1167.","journal-title":"Sci Transl Med"},{"key":"2061_CR5","doi-asserted-by":"publisher","first-page":"330","DOI":"10.3389\/fimmu.2017.00330","volume":"8","author":"N Patsoukis","year":"2017","unstructured":"Patsoukis N, Weaver JD, Strauss L, Herbel C, Seth P, Boussiotis VA. Immunometabolic regulations mediated by coinhibitory receptors and their impact on T cell immune responses. Front Immunol. 2017;8:330.","journal-title":"Front Immunol"},{"key":"2061_CR6","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1182\/blood-2016-09-692541","volume":"129","author":"MA Lunning","year":"2017","unstructured":"Lunning MA, Vose JM. Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma. Blood. 2017;129:1095\u2013102.","journal-title":"Blood"},{"key":"2061_CR7","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3960\/jslrt.17019","volume":"57","author":"M Fujisawa","year":"2017","unstructured":"Fujisawa M, Chiba S, Sakata-Yanagimoto M. Recent progress in the understanding of angioimmunoblastic T-cell lymphoma. J Clin Exp Hematop. 2017;57:109\u201319.","journal-title":"J Clin Exp Hematop"},{"key":"2061_CR8","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.ccell.2019.07.008","volume":"36","author":"L Mondrag\u00f3n","year":"2019","unstructured":"Mondrag\u00f3n L, Mhaidly R, De Donatis GM, Tosolini M, Dao P, Martin AR, et al. GAPDH overexpression in the T cell lineage promotes angioimmunoblastic T cell lymphoma through an NF-\u03baB-dependent mechanism. Cancer Cell. 2019;36:268\u2013287.e10.","journal-title":"Cancer Cell"},{"key":"2061_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-020-00259-x","volume":"9","author":"R Mhaidly","year":"2020","unstructured":"Mhaidly R, Krug A, Gaulard P, Lemonnier F, Ricci J-E, Verhoeyen E. New preclinical models for angioimmunoblastic T-cell lymphoma: filling the GAP. Oncogenesis. 2020;9:73.","journal-title":"Oncogenesis"},{"key":"2061_CR10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13046-024-02952-w","volume":"43","author":"A Krug","year":"2024","unstructured":"Krug A, Tosolini M, Madji Hounoum B, Fourni\u00e9 J-J, Geiger R, Pecoraro M, et al. Inhibition of choline metabolism in an angioimmunoblastic T-cell lymphoma preclinical model reveals a new metabolic vulnerability as possible target for treatment. J Exp Clin Cancer Res. 2024;43:43.","journal-title":"J Exp Clin Cancer Res"},{"key":"2061_CR11","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1182\/blood-2013-11-536359","volume":"123","author":"J Iqbal","year":"2014","unstructured":"Iqbal J, Wright G, Wang C, Rosenwald A, Gascoyne RD, Weisenburger DD, et al. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood. 2014;123:2915\u201323.","journal-title":"Blood"},{"key":"2061_CR12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s10048-006-0032-6","volume":"7","author":"RB Roth","year":"2006","unstructured":"Roth RB, Hevezi P, Lee J, Willhite D, Lechner SM, Foster AC, et al. Gene expression analyses reveal molecular relationships among 20 regions of the human CNS. Neurogenetics. 2006;7:67\u201380.","journal-title":"Neurogenetics"},{"key":"2061_CR13","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1158\/0008-5472.CAN-16-1204","volume":"77","author":"\u00c9 Audet-Walsh","year":"2017","unstructured":"Audet-Walsh \u00c9, Yee T, McGuirk S, Vernier M, Ouellet C, St-Pierre J, et al. Androgen-dependent repression of ERR\u03b3 reprograms metabolism in prostate cancer. Cancer Res. 2017;77:378\u201389.","journal-title":"Cancer Res"},{"key":"2061_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7692","volume":"6","author":"N Patsoukis","year":"2015","unstructured":"Patsoukis N, Bardhan K, Chatterjee P, Sari D, Liu B, Bell LN, et al. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat Commun. 2015;6:6692.","journal-title":"Nat Commun"},{"key":"2061_CR15","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.cmet.2020.11.007","volume":"32","author":"RJ Arg\u00fcello","year":"2020","unstructured":"Arg\u00fcello RJ, Combes AJ, Char R, Gigan J-P, Baaziz AI, Bousiquot E, et al. SCENITH: a flow cytometry-based method to functionally profile energy metabolism with single-cell resolution. Cell Metab. 2020;32:1063\u20131075.e7.","journal-title":"Cell Metab"},{"key":"2061_CR16","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/s42255-020-0256-z","volume":"2","author":"RI Klein Geltink","year":"2020","unstructured":"Klein Geltink RI, Edwards-Hicks J, Apostolova P, O\u2019Sullivan D, Sanin DE, Patterson AE, et al. Metabolic conditioning of CD8+ effector T cells for adoptive cell therapy. Nat Metab. 2020;2:703\u201316.","journal-title":"Nat Metab"},{"key":"2061_CR17","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.4049\/jimmunol.1003613","volume":"186","author":"RD Michalek","year":"2011","unstructured":"Michalek RD, Gerriets VA, Jacobs SR, Macintyre AN, MacIver NJ, Mason EF, et al. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J Immunol. 2011;186:3299\u2013303.","journal-title":"J Immunol"},{"key":"2061_CR18","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.cell.2017.04.004","volume":"169","author":"MD Buck","year":"2017","unstructured":"Buck MD, Sowell RT, Kaech SM, Pearce EL. Metabolic instruction of immunity. Cell. 2017;169:570\u201386.","journal-title":"Cell"},{"key":"2061_CR19","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/s41568-020-0273-y","volume":"20","author":"RD Leone","year":"2020","unstructured":"Leone RD, Powell JD. Metabolism of immune cells in cancer. Nat Rev Cancer. 2020;20:516\u201331.","journal-title":"Nat Rev Cancer"},{"key":"2061_CR20","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1038\/s41591-018-0052-4","volume":"24","author":"JR Molina","year":"2018","unstructured":"Molina JR, Sun Y, Protopopova M, Gera S, Bandi M, Bristow C, et al. An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nat Med. 2018;24:1036\u201346.","journal-title":"Nat Med"},{"key":"2061_CR21","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1200\/JCO.21.01815","volume":"40","author":"E Bachy","year":"2022","unstructured":"Bachy E, Camus V, Thieblemont C, Sibon D, Casasnovas R-O, Ysebaert L, et al. Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: results of the Ro-CHOP phase III study (Conducted by LYSA). J Clin Oncol. 2022;40:242\u201351.","journal-title":"J Clin Oncol"},{"key":"2061_CR22","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.3390\/cancers14102392","volume":"14","author":"A Krug","year":"2022","unstructured":"Krug A, Tari G, Saidane A, Gaulard P, Ricci J-E, Lemonnier F, et al. Novel T follicular helper-like T-cell lymphoma therapies: from preclinical evaluation to clinical reality. Cancers (Basel). 2022;14:2392.","journal-title":"Cancers (Basel)"},{"key":"2061_CR23","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41591-022-02103-8","volume":"29","author":"TA Yap","year":"2023","unstructured":"Yap TA, Daver N, Mahendra M, Zhang J, Kamiya-Matsuoka C, Meric-Bernstam F, et al. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat Med. 2023;29:115\u201326.","journal-title":"Nat Med"},{"key":"2061_CR24","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1038\/ni.2985","volume":"15","author":"KJ Oestreich","year":"2014","unstructured":"Oestreich KJ, Read KA, Gilbertson SE, Hough KP, McDonald PW, Krishnamoorthy V, et al. Bcl-6 directly represses the gene program of the glycolysis pathway. Nat Immunol. 2014;15:957\u201364.","journal-title":"Nat Immunol"},{"key":"2061_CR25","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.immuni.2015.08.017","volume":"43","author":"JP Ray","year":"2015","unstructured":"Ray JP, Staron MM, Shyer JA, Ho P-C, Marshall HD, Gray SM, et al. The Interleukin-2-mTORc1 Kinase Axis Defines the Signaling, Differentiation, and Metabolism of T Helper 1 and Follicular B Helper T Cells. Immunity. 2015;43:690\u2013702.","journal-title":"Immunity"},{"key":"2061_CR26","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s12185-016-2159-z","volume":"105","author":"S Nishizawa","year":"2017","unstructured":"Nishizawa S, Sakata-Yanagimoto M, Hattori K, Muto H, Nguyen T, Izutsu K, et al. BCL6 locus is hypermethylated in angioimmunoblastic T-cell lymphoma. Int J Hematol. 2017;105:465\u20139.","journal-title":"Int J Hematol"},{"key":"2061_CR27","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.bbcan.2018.06.005","volume":"1870","author":"L Sun","year":"2018","unstructured":"Sun L, Suo C, Li S-T, Zhang H, Gao P. Metabolic reprogramming for cancer cells and their microenvironment: beyond the Warburg effect. Biochim Biophys Acta Rev Cancer. 2018;1870:51\u201366.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"2061_CR28","doi-asserted-by":"publisher","first-page":"e005644","DOI":"10.1136\/jitc-2022-005644","volume":"10","author":"N Imahashi","year":"2022","unstructured":"Imahashi N, Basar R, Huang Y, Wang F, Baran N, Banerjee PP, et al. Activated B cells suppress T-cell function through metabolic competition. J Immunother Cancer. 2022;10:e005644.","journal-title":"J Immunother Cancer"},{"key":"2061_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.987227","volume":"13","author":"Z Chen","year":"2022","unstructured":"Chen Z, Zhu Q, Deng X, Yao W, Zhang W, Liu W, et al. Angioimmunoblastic T-cell lymphoma with predominant CD8+ tumor-infiltrating T-cells is a distinct immune pattern with an immunosuppressive microenvironment. Front Immunol. 2022;13:987227.","journal-title":"Front Immunol"},{"key":"2061_CR30","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","volume":"162","author":"C-H Chang","year":"2015","unstructured":"Chang C-H, Qiu J, O\u2019Sullivan D, Buck MD, Noguchi T, Curtis JD, et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell. 2015;162:1229\u201341.","journal-title":"Cell"},{"key":"2061_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.864225","volume":"13","author":"R Chao","year":"2022","unstructured":"Chao R, Nishida M, Yamashita N, Tokumasu M, Zhao W, Kudo I, et al. Nutrient condition in the microenvironment determines essential metabolisms of CD8+ T cells for enhanced IFN\u03b3 production by metformin. Front Immunol. 2022;13:864225.","journal-title":"Front Immunol"},{"key":"2061_CR32","doi-asserted-by":"publisher","first-page":"e002773","DOI":"10.1136\/jitc-2021-002773","volume":"9","author":"R Veeramachaneni","year":"2021","unstructured":"Veeramachaneni R, Yu W, Newton JM, Kemnade JO, Skinner HD, Sikora AG, et al. Metformin generates profound alterations in systemic and tumor immunity with associated antitumor effects. J Immunother Cancer. 2021;9:e002773.","journal-title":"J Immunother Cancer"},{"key":"2061_CR33","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.jhep.2022.03.010","volume":"77","author":"S Wabitsch","year":"2022","unstructured":"Wabitsch S, McCallen JD, Kamenyeva O, Ruf B, McVey JC, Kabat J, et al. Metformin treatment rescues CD8+ T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD. J Hepatol. 2022;77:748\u201360.","journal-title":"J Hepatol"},{"key":"2061_CR34","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.copbio.2020.11.013","volume":"68","author":"J Leca","year":"2021","unstructured":"Leca J, Fortin J, Mak TW. Illuminating the cross-talk between tumor metabolism and immunity in IDH-mutated cancers. Curr Opin Biotechnol. 2021;68:181\u20135.","journal-title":"Curr Opin Biotechnol"},{"key":"2061_CR35","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1158\/2159-8290.CD-19-0811","volume":"10","author":"H Zhang","year":"2020","unstructured":"Zhang H, Schaefer A, Wang Y, Hodge RG, Blake DR, Diehl JN, et al. Gain-of-function RHOA mutations promote focal adhesion kinase activation and dependency in diffuse gastric cancer. Cancer Discov. 2020;10:288\u2013305.","journal-title":"Cancer Discov"},{"key":"2061_CR36","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/ng.2984","volume":"46","author":"M Kakiuchi","year":"2014","unstructured":"Kakiuchi M, Nishizawa T, Ueda H, Gotoh K, Tanaka A, Hayashi A, et al. Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma. Nat Genet. 2014;46:583\u20137.","journal-title":"Nat Genet"},{"key":"2061_CR37","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/ng.2872","volume":"46","author":"M Sakata-Yanagimoto","year":"2014","unstructured":"Sakata-Yanagimoto M, Enami T, Yoshida K, Shiraishi Y, Ishii R, Miyake Y, et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet. 2014;46:171\u20135.","journal-title":"Nat Genet"},{"key":"2061_CR38","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ccell.2018.01.001","volume":"33","author":"JR Cortes","year":"2018","unstructured":"Cortes JR, Ambesi-Impiombato A, Couronn\u00e9 L, Quinn SA, Kim CS, da Silva Almeida AC, et al. RHOA G17V induces T follicular helper cell specification and promotes lymphomagenesis. Cancer Cell. 2018;33:259\u2013273.e7.","journal-title":"Cancer Cell"},{"key":"2061_CR39","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1182\/blood-2017-11-818617","volume":"132","author":"SY Ng","year":"2018","unstructured":"Ng SY, Brown L, Stevenson K, deSouza T, Aster JC, Louissaint A, et al. RhoA G17V is sufficient to induce autoimmunity and promotes T-cell lymphomagenesis in mice. Blood. 2018;132:935\u201347.","journal-title":"Blood"},{"key":"2061_CR40","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.ccell.2023.01.003","volume":"41","author":"J Leca","year":"2023","unstructured":"Leca J, Lemonnier F, Meydan C, Foox J, El Ghamrasni S, Mboumba D-L, et al. IDH2 and TET2 mutations synergize to modulate T Follicular Helper cell functional interaction with the AITL microenvironment. Cancer Cell. 2023;41:323\u2013339.e10.","journal-title":"Cancer Cell"},{"key":"2061_CR41","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2015.07.016","volume":"162","author":"K Birsoy","year":"2015","unstructured":"Birsoy K, Wang T, Chen WW, Freinkman E, Abu-Remaileh M, Sabatini DM. An essential role of the mitochondrial electron transport chain in cell proliferation is to enable aspartate synthesis. Cell. 2015;162:540\u201351.","journal-title":"Cell"},{"key":"2061_CR42","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ccell.2019.06.003","volume":"36","author":"I Baccelli","year":"2019","unstructured":"Baccelli I, Gareau Y, Lehnertz B, Gingras S, Spinella J-F, Corneau S, et al. Mubritinib targets the electron transport chain complex I and reveals the landscape of oXPHOS dependency in acute myeloid leukemia. Cancer Cell. 2019;36:84\u201399.e8.","journal-title":"Cancer Cell"},{"key":"2061_CR43","doi-asserted-by":"publisher","first-page":"14276","DOI":"10.1021\/acs.jmedchem.0c01013","volume":"63","author":"Y Xu","year":"2020","unstructured":"Xu Y, Xue D, Bankhead A, Neamati N. Why all the fuss about oxidative phosphorylation (OXPHOS)? J Med Chem. 2020;63:14276\u2013307.","journal-title":"J Med Chem"},{"key":"2061_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2022.155223","volume":"133","author":"CR Triggle","year":"2022","unstructured":"Triggle CR, Mohammed I, Bshesh K, Marei I, Ye K, Ding H, et al. Metformin: is it a drug for all reasons and diseases? Metabolism. 2022;133:155223.","journal-title":"Metabolism"},{"key":"2061_CR45","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1042\/BJ20140620","volume":"462","author":"HR Bridges","year":"2014","unstructured":"Bridges HR, Jones AJY, Pollak MN, Hirst J. Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria. Biochem J. 2014;462:475\u201387.","journal-title":"Biochem J"},{"key":"2061_CR46","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/bco2.187","volume":"4","author":"NF Wang","year":"2023","unstructured":"Wang NF, Jue TR, Holst J, Gunter JH. Systematic review of antitumour efficacy and mechanism of metformin activity in prostate cancer models. BJUI Compass. 2023;4:44\u201358.","journal-title":"BJUI Compass"},{"key":"2061_CR47","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1097\/j.pain.0000000000000893","volume":"158","author":"K Krukowski","year":"2017","unstructured":"Krukowski K, Ma J, Golonzhka O, Laumet GO, Gutti T, van Duzer JH, et al. HDAC6 inhibition effectively reverses chemotherapy-induced peripheral neuropathy. Pain. 2017;158:1126\u201337.","journal-title":"Pain"},{"key":"2061_CR48","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1002\/cam4.112","volume":"2","author":"P Ellinghaus","year":"2013","unstructured":"Ellinghaus P, Heisler I, Unterschemmann K, Haerter M, Beck H, Greschat S, et al. BAY 87-2243, a highly potent and selective inhibitor of hypoxia-induced gene activation has antitumor activities by inhibition of mitochondrial complex I. Cancer Med. 2013;2:611\u201324.","journal-title":"Cancer Med"},{"key":"2061_CR49","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/s41574-023-00833-4","volume":"19","author":"M Foretz","year":"2023","unstructured":"Foretz M, Guigas B, Viollet B. Metformin: update on mechanisms of action and repurposing potential. Nat Rev Endocrinol. 2023;19:460\u201376.","journal-title":"Nat Rev Endocrinol"},{"key":"2061_CR50","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1111\/bjh.15997","volume":"186","author":"Y Wang","year":"2019","unstructured":"Wang Y, Maurer MJ, Larson MC, Allmer C, Feldman AL, Bennani NN, et al. Impact of metformin use on the outcomes of newly diagnosed diffuse large B-cell lymphoma and follicular lymphoma. Br J Haematol. 2019;186:820\u20138.","journal-title":"Br J Haematol"},{"key":"2061_CR51","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.cmet.2019.02.002","volume":"29","author":"J Chiche","year":"2019","unstructured":"Chiche J, Reverso-Meinietti J, Mouchotte A, Rubio-Pati\u00f1o C, Mhaidly R, Villa E, et al. GAPDH expression predicts the response to R-CHOP, the tumor metabolic status, and the response of DLBCL patients to metabolic inhibitors. Cell Metab. 2019;29:1243\u20131257.e10.","journal-title":"Cell Metab"},{"key":"2061_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-12-323","volume":"12","author":"B Li","year":"2011","unstructured":"Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics. 2011;12:323.","journal-title":"BMC Bioinformatics"},{"key":"2061_CR53","doi-asserted-by":"publisher","first-page":"4952","DOI":"10.1182\/blood-2006-10-055145","volume":"109","author":"de Leval","year":"2007","unstructured":"de Leval, Rickman L, Thielen DS, Reynies C, de A, Huang Y-L, et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood. 2007;109:4952\u201363.","journal-title":"Blood"},{"key":"2061_CR54","doi-asserted-by":"publisher","first-page":"D687","DOI":"10.1093\/nar\/gkab1028","volume":"50","author":"M Gillespie","year":"2022","unstructured":"Gillespie M, Jassal B, Stephan R, Milacic M, Rothfels K, Senff-Ribeiro A, et al. The reactome pathway knowledgebase 2022. Nucleic Acids Res. 2022;50:D687\u2013D692.","journal-title":"Nucleic Acids Res"},{"key":"2061_CR55","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Cell Death Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41420-024-02061-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-024-02061-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-024-02061-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T03:37:03Z","timestamp":1718854623000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41420-024-02061-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,19]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2061"],"URL":"https:\/\/doi.org\/10.1038\/s41420-024-02061-9","relation":{},"ISSN":["2058-7716"],"issn-type":[{"value":"2058-7716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,19]]},"assertion":[{"value":"24 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All mouse experimental procedures were carried out in compliance with protocols approved by the local ethical and experimentation committee (SBEA, Nice, France, authorization no. 28790-2020121715244498 and B0608820). All human blood and tissues were obtained after informed consent and approval were obtained by the ethical commission of the hospitals according to the Helsinki Declaration.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"292"}}